Pfizer Inc (PFE)vsTesla Inc (TSLA)
PFE
Pfizer Inc
$25.68
-1.40%
HEALTHCARE · Cap: $150.92B
TSLA
Tesla Inc
$428.35
+4.02%
CONSUMER CYCLICAL · Cap: $1.55T
Smart Verdict
WallStSmart Research — data-driven comparison
Tesla Inc generates 55% more annual revenue ($97.88B vs $63.32B). PFE leads profitability with a 11.8% profit margin vs 4.0%. TSLA appears more attractively valued with a PEG of 5.40. PFE earns a higher WallStSmart Score of 55/100 (C).
PFE
Buy55
out of 100
Grade: C
TSLA
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+29.4%
Fair Value
$37.48
Current Price
$25.68
$11.80 discount
Margin of Safety
-57.7%
Fair Value
$261.17
Current Price
$428.35
$167.18 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.6%
Large-cap with strong market position
Reasonable price relative to book value
Generating 2.2B in free cash flow
Mega-cap, among the largest globally
Conservative balance sheet, low leverage
15.8% revenue growth
Generating 1.4B in free cash flow
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 10.1%
Trading at 19.6x book value
ROE of 4.9% — below average capital efficiency
4.0% margin — thin
Operating margin of 4.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : PFE
The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.
Bull Case : TSLA
The strongest argument for TSLA centers on Market Cap, Debt/Equity, Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TSLA
The primary concerns for TSLA are Price/Book, Return on Equity, Profit Margin. A P/E of 384.9x leaves little room for execution misses. Thin 4.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
PFE profiles as a value stock while TSLA is a growth play — different risk/reward profiles.
TSLA carries more volatility with a beta of 1.79 — expect wider price swings.
TSLA is growing revenue faster at 15.8% — sustainability is the question.
PFE generates stronger free cash flow (2.2B), providing more financial flexibility.
Bottom Line
PFE scores higher overall (55/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Tesla Inc
CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA
Tesla, Inc. is an American electric vehicle and clean energy company based in Palo Alto, California. Tesla's current products include electric cars, battery energy storage from home to grid-scale, solar panels and solar roof tiles, as well as other related products and services. In 2020, Tesla had the highest sales in the plug-in and battery electric passenger car segments, capturing 16% of the plug-in market (which includes plug-in hybrids) and 23% of the battery-electric (purely electric) market. Through its subsidiary Tesla Energy, the company develops and is a major installer of solar photovoltaic energy generation systems in the United States. Tesla Energy is also one of the largest global suppliers of battery energy storage systems, with 3 GWh of battery storage supplied in 2020.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?